Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2024-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Optipharm' (주식회사 옵티팜) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business descriptions, and management disclosures, which is characteristic of a formal quarterly financial filing in the Korean market (DART system). It is not an announcement of a report, but the report itself. 9M 2024
2024-11-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). It details specific share transactions (purchases) made by a director (Kim Hyun-il) of the company Optipharm. This type of filing is a standard disclosure for insider trading/director dealings.
2024-11-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Kim Hyun-il) of Optipharm. It details a change in share ownership due to an open-market purchase (장내매수). This type of filing is a standard regulatory disclosure for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-09-25 Korean
신규시설투자등
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from Optipharm regarding a new facility investment (capital expenditure). It details the investment amount, purpose (GMP production line), and board approval date. Since it does not fit into specific categories like M&A, share issues, or financial reports, and is a standard regulatory disclosure of corporate activity, it is classified as a Regulatory Filing (RNS).
2024-09-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share acquisition transactions (insider trading) by a director (CEO Kim Hyun-il) of Optipharm. This falls under the category of Director's Dealing (DIRS), which covers personal share transactions by company directors and executives.
2024-08-20 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Optipharm' (주식회사 옵티팜) covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business descriptions, and management disclosures required for a formal interim report. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.